Compare e l f Beauty Inc (ELF) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

ELF Beauty trades at $109.23, up 4.0% today, showing strong momentum with three consecutive earnings beats and bullish technical signals. The stock's premium valuation (P/E 108.12) reflects high growth expectations as revenue surged to $1.31B in 2025 with 74.44% gross margins. Recent expansion into European markets via Sephora and innovative marketing campaigns like the 'Mirror Mix' album highlight aggressive growth strategies. Analyst sentiment is mixed with 48% buy ratings but a consensus price target of $95.91 suggests caution near current levels.

ELF's growth trajectory remains compelling with international expansion and product innovation driving revenue, though elevated valuation and declining net margins (3.38% in 2026) pose risks. Institutional buying supports bullish sentiment, but investors should monitor execution of expansion plans and competitive pressures in the beauty sector. The stock trades above analyst targets, indicating limited near-term upside without further earnings surprises.

Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.

Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.